Combination Therapy For CNS Lymphoma

Tech ID: 33640 / UC Case 2023-138-0

Technology Description

There are currently no effective therapies for CNS lymphoma. Although B-cell malignancies express CD19, few therapeutic modalities (including CAR-T cells and bispecific T-cell engager antibodies) have overcome severe CNS neurotoxicity. New research suggests that CD19 expression at BBB may mediate neurotoxicity.  Our inventor has shown regression of highly refractory CNS lymphoma with tafasitamab and lenalidomide. 

Stage of Development

Phase 2 L-MIND trial in patients with refractory non-Hodgkin lymphoma.

Related Materials

Patent Status

Patent Pending


Learn About UC TechAlerts - Save Searches and receive new technology matches

Other Information


Refractory CNS Lymphoma, B Cell Malignancy, CD19, Tasasitamab, Lenalidomide

Categorized As